Milrinone inhibits hypoxia or hydrogen dioxide-induced persistent sodium current in ventricular myocytes

Jie Zheng1, Jihua Ma, Peihua Zhang

  • 1Cardio-Electrophysiological Research Laboratory, Medical College, Wuhan University of Science and Technology, Wuhan, Hubei, China.

Insights

Milrinone effectively reduces persistent sodium current (I(Na.P)) in heart cells, even under conditions like hypoxia or hydrogen peroxide exposure. This action, linked to increased cyclic adenosine monophosphate (cAMP), may offer therapeutic benefits for heart conditions.

Area of Science:

  • Cardiology
  • Molecular Pharmacology
  • Cell Physiology

Background:

  • Increased persistent sodium current (I(Na.P)) is linked to cellular calcium overload.
  • I(Na.P) is a potential therapeutic target for ischemia and heart failure.
  • Milrinone, a phosphodiesterase inhibitor, increases cyclic adenosine monophosphate (cAMP) and has a positive inotropic effect.

Purpose of the Study:

  • To investigate the effect of milrinone on I(Na.P) under pathological conditions.
  • To determine if milrinone affects I(Na.P) enhanced by hypoxia or hydrogen peroxide in guinea pig ventricular myocytes.

Main Methods:

  • Electrophysiological recordings of I(Na.P) in guinea pig ventricular myocytes.
  • Application of milrinone, cAMP, H-89 (a protein kinase inhibitor), hypoxia, and hydrogen peroxide.
  • Measurement of action potential duration at 90% repolarization (APD(90)).

Main Results:

  • Milrinone and cAMP decreased I(Na.P) in control conditions; H-89 blocked milrinone's effect.
  • Milrinone reduced hypoxia-induced and hydrogen peroxide-enhanced I(Na.P).
  • Milrinone shortened APD(90) prolonged by hydrogen peroxide, an effect partially reversed by tetrodotoxin (TTX).

Conclusions:

  • Milrinone inhibits I(Na.P) under normal, hypoxic, and hydrogen peroxide-induced conditions.
  • Milrinone's inhibition of I(Na.P) and shortening of APD(90) in pathological states are associated with increased intracellular cAMP.
  • These findings suggest milrinone's potential therapeutic role in conditions involving I(Na.P) dysfunction.

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...